We have two broad areas of research interest. The first area focuses on understanding the mechanism of tumor-selective, radiosensitization of NSCLC or PDA using a novel NQO1 bioactivatable drug. Our second area of interest is in investigating the effects of the immune system (STING and checkpoint inhibitors) on the efficacy of NQO1 bioactivatable drugs.
Active Research
- NQO1 bioactivatable drugs as radiosensitizer
- Synergistic effects of NQO1 bioactivatable drugs and PARP inhibitors
- Targeting NQO1+ tumor to trigger innate and adaptive immunity
